Innovation Pharmaceuticals Inc. - FORM 10-K - EX-23.1 - CONSENT - September 8, 2017

Attached files

file filename
10-K - FORM 10-K - Innovation Pharmaceuticals Inc.ipix_10k.htm
EX-32.2 - CERTIFICATION - Innovation Pharmaceuticals Inc.ipix_ex322.htm
EX-32.1 - CERTIFICATION - Innovation Pharmaceuticals Inc.ipix_ex321.htm
EX-31.2 - CERTIFICATION - Innovation Pharmaceuticals Inc.ipix_ex312.htm
EX-31.1 - CERTIFICATION - Innovation Pharmaceuticals Inc.ipix_ex311.htm
EX-10.16 - FORM OF NON-QUALIFIED STOCK OPTION AGREEMENT - Innovation Pharmaceuticals Inc.ipix_ex1016.htm
EX-10.7 - REGISTRATION RIGHTS AGREEMENT - Innovation Pharmaceuticals Inc.ipix_ex107.htm
EX-10.6 - COMMON STOCK PURCHASE AGREEMENT - Innovation Pharmaceuticals Inc.ipix_ex106.htm
EX-5.1 - OPINION OF GARY R. HENRIE, ESQ. - Innovation Pharmaceuticals Inc.ipix_ex51.htm
EX-3.2 - AMENDED AND RESTATED BYLAWS - Innovation Pharmaceuticals Inc.ipix_ex32.htm

EXHIBIT 23.1

 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

We consent to the incorporation by reference in the Registration Statements on Form S-3 (File No. 333-199725) and Form S-8 (File No. 333-212549, 333-323551) of Innovation Pharmaceuticals Inc. (“the Company”) of our report dated September 8, 2017, relating to the financial statements and the effectiveness of internal control over financial reporting, which appears on Form 10-K for the year ended June 30, 2017.

 

 

/s/ BAKER TILLY VIRCHOW KRAUSE, LLP

 

Minneapolis, Minnesota

September 8, 2017

 

Stock widget

Investing forum

Innovation Pharmaceuticals Inc. Reports